Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03254784 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
A Phase 1 study of Psoriasis and Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT03254784 is a Phase 1 study of Psoriasis and Systemic Lupus Erythematosus that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 49 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03254784, a Phase 1 study of Psoriasis and Systemic Lupus Erythematosus, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate BMS-986165 tablet formulation versus BMS-986165 capsule formulation. This study will also evaluate the effect of a high-fat/ high-calorie meal and increased gastric pH on the BMS-986165 tablet formulation.
Conditions Studied
Interventions
- DRUG BMS-986165 Capsule
- DRUG BMS-986165 Tablet
Study Locations (1)
Kansas
- PRA Health Sciences - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-09-13 |
| Est. Completion | 2017-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03254784
The ClinicalTrials.gov registry entry for NCT03254784 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (90% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which BMS-986165 Capsule is the first listed.
NCT03254784 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT03254784 about?
NCT03254784 is a clinical study titled "A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation". The purpose of this study is to evaluate BMS-986165 tablet formulation versus BMS-986165 capsule formulation. This study will also evaluate the effect of a high-fat/ high-calorie meal and increased gastric pH on the BMS-986165 tablet formulation.
What is the current status of trial NCT03254784?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2017-09-13. Estimated completion is 2017-11-15.
What conditions does trial NCT03254784 study?
This clinical trial studies the following conditions: Psoriasis, Systemic Lupus Erythematosus, Inflammatory Bowel Diseases, Arthritic Psoriasis.
What interventions are being tested in trial NCT03254784?
The interventions under investigation include: BMS-986165 Capsule (DRUG), BMS-986165 Tablet (DRUG).
Who is sponsoring clinical trial NCT03254784?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03254784 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.